Compare PRME & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | RGR |
|---|---|---|
| Founded | 2019 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 617.8M |
| IPO Year | 2022 | 1994 |
| Metric | PRME | RGR |
|---|---|---|
| Price | $2.89 | $38.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $7.56 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 2.8M | 97.2K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $4,632,000.00 | ★ $546,057,000.00 |
| Revenue This Year | $7.06 | $2.38 |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | ★ N/A | $3,888.00 |
| Revenue Growth | ★ 55.28 | 1.94 |
| 52 Week Low | $1.40 | $28.33 |
| 52 Week High | $6.94 | $48.21 |
| Indicator | PRME | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 42.98 |
| Support Level | $2.68 | $38.60 |
| Resistance Level | $3.72 | $38.89 |
| Average True Range (ATR) | 0.28 | 0.87 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 21.98 | 15.32 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.